China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical (TYO: 4536) for the commercialization of ARVN001, an innovative triamcinolone acetonide suprachoroidal injectable suspension. This partnership marks a significant step in the expansion of ophthalmic treatments, with Santen securing exclusive commercialization rights in mainland China through a deal that includes an upfront payment and milestone payments totaling up to USD 85 million.
ARVN001: A Breakthrough in Ophthalmic Treatment
ARVN001 leverages the patented SCS Microinjector technology to address uveitic macular edema (UME) and other ophthalmic conditions currently under development. Already approved in the US under the trade name Xipere, ARVN001 stands as the sole approved suprachoroidal therapy for UME. The product was licensed from Clearside Biomedical, Inc., granting Arctic Vision the development and commercialization rights across the Asia Pacific region.
Expanding Therapeutic Horizons
The agreement not only solidifies Santen’s position in the Chinese market but also accelerates the availability of ARVN001 to patients in need. The drug’s journey continues with ongoing assessments in studies for other retinal diseases, following the release of positive topline results from a Phase III clinical trial in China in July this year. This collaboration is poised to enhance access to advanced ophthalmic treatments, marking a new chapter in the fight against vision-threatening conditions.-Fineline Info & Tech
Leave a Reply